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INTRODUCTION
The goal of an antibody-drug conjugate (ADC) as an anti-cancer therapeutic is to deliver a highly effective cytotoxic agent specifically to the tumor, while sparing normal tissue, thereby effecting clinically meaningful responses in patients. The specificity of an ADC arises from the antibody component, which binds an antigen that ideally, is highly expressed in tumor cells and minimally or not expressed elsewhere (1) (2) (3) (4) .
The first ADC approved by the United States (US) Food and Drug Administration (FDA), gemtuzumab ozogamicin (Mylotarg®; Wyeth/Pfizer) targeted CD33 using calicheamicin as the payload and was indicated for the treatment of acute myelogenous leukemia (5) . However, Mylotarg was withdrawn from the US market due to inadequate clinical activity and considerable toxicity. More recently, brentuximab vedotin (ADCETRIS®; Seattle Genetics) (6) , an anti-CD30-auristatin conjugate, was approved for the treatment of relapsed systemic anaplastic large cell lymphoma and Hodgkin's lymphoma, and trastuzumab emtansine (KADCYLA®; Genentech) (7), which comprises an anti-HER2 antibody conjugated to the maytansine derivative DM1, was approved for the treatment of advanced Her-2 positive breast cancer. Currently more than 30 ADCs are in clinical development (8) .
Herein, we describe a novel ADC (AGS16F) that targets an antigen largely unknown in oncology, ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3; also known as CD203c). ENPP3 is a basophil activation marker and is one of 7 members of a family of cell-surface ectonucleotide pyrophosphatases/phosphodiesterases (9) (10) (11) (12) (13) (14) . The extracellular domain of ENPP3, a type II transmembrane protein, comprises a nuclease-like domain, a catalytic domain and a somatomedin B-like domain (including an RGD integrin-binding motif). ENPP3 hydrolyzes extracellular pyrophosphate or phosphodiester bonds (12, 15) as well as intracellular nucleotides involved in glycosyltransferase activity (16) . Expression of ENPP3 has been reported in neoplastic mast cells in the context of mastocytosis (17, 18) , in acute basophilic leukemia (19) , in some colon cancer samples (20) , and in neoplastic cells of the bile duct (21) . However, a functional role for ENPP3 in cancer has not been elucidated.
The current report demonstrates that ENPP3 is highly expressed in renal cell carcinoma (RCC), but has restricted expression in normal tissues, with the exception of the kidney. We also show that an ADC targeting ENPP3 is rapidly internalized and trafficked to lysosomes, and has significant anti-tumor activity. Thus, an ENPP3-targeted ADC is a promising therapeutic agent for the treatment of renal and other cancers that show high expression of ENPP3.
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Materials and Methods

Suppression subtractive hybridization
Suppression subtractive hybridization (SSH) was carried out with the PCR-Select cDNA Subtraction Kit (Clontech; Palo Alto, CA) using a cDNA library generated from tumor specimens from patients with RCC and a cDNA library generated from 9 normal tissues (stomach, skeletal muscle, lung, brain, liver, kidney, pancreas, small intestine and heart).
RT-PCR expression analysis
First strand cDNAs were generated using SuperScript® reverse transcriptase (Invitrogen) and Oligo (dT)12-18 priming according to manufacturer's protocol. cDNAs were normalized using GAPDH primers. To determine expression levels of ENPP3, 5µl of normalized cDNA obtained from a panel of normal tissues and patient cancer specimens were amplified using ENPP3 specific primers. PCR products were analyzed by agarose gel electrophoresis and signal quantitated by densitometry.
Generation of recombinant proteins
To express the extracellular domains (ECD) of human ENPP3, its closest family members (ENPP1 and ENPP2) and its cynomolgus monkey, rat and mouse orthologs, cDNA was amplified from normal tissues, fused to Myc/His tag followed by a stop codon and cloned into pAPtag-5 mammalian expression vector (GenHunter Corporation, Nashville, TN). Constructs were transfected into 293T cells and recombinant proteins were purified from culture supernatant on Ni-NTA His-Bind column (Novagen).
Antibody generation
Anti-human ENPP3 monoclonal antibodies were generated using standard hybridoma technology in the genetically engineered Xenomouse TM (Amgen, Inc.) (22) following immunization of mice with the human ENPP3 ECD (amino acids 48 to 875). The variable heavy chain and kappa light chains of selected antibodies were sequenced from the corresponding hybridoma and cloned into the pEE12.4 mammalian cell expression vector (Lonza; Wayne, PA). The plasmid was transfected into Chinese hamster ovary CHOK1SV host cells (Lonza).
Conjugation of Antibodies and Cytotoxic Agents
Purified antibodies were conjugated with monomethyl auristatin E (MMAE) via the cleavable linker maleimidocaproylvaline-citrulline-p-aminobenzyloxycarbonyl (vc) or to monomethyl auristatin F (MMAF) via the linker maleimidocaproyl (mc) as previously described (licensed from Seattle Genetics, Inc.) (23, 24) . The drug to antibody ratio was approximately 4:1. The anti-ENPP3 IgG 2 antibody AGS16-7.8 produced from the hybridoma or CHO cells was conjugated to mcMMAF to produce AGS-16M8F or AGS-16C3F, respectively.
Immunohistochemistry
A mouse anti-ENPP3 monoclonal antibody (M16-48(4)29.1.1.1) was generated by immunizing Balb/c mice with the ENPP3 ECD. Sections were stained in a Biogenex i6000 autostainer (Biogenex, San Ramon, CA). Antigen retrieval was carried out using proteinase K (Dako, Carpenteria, CA). M16-48(4)29.1.1 or MOPC21 (negative control), both at 5 μg/mL, were applied to the sections and incubated for 1 hour at room temperature. ENPP3 was visualized using the Biogenex Super Sensitive Polymer-horseradish peroxidase IHC detection kit with 3.3'-diaminobenzidine (DAB) as the chromogen.
Cytotoxicity assay
KU812 basophilic leukemia cells (ATCC, Manassas, VA) were incubated with serially diluted ADC or isotype-control ADC at 37 ⁰C in a CO 2 incubator. Cell viability was measured after 5 to 7 days using the AlamarBlue® reagent (Life Technologies, Carlsbad, CA). Percent survival was calculated as the number of live cells in treated wells compared to the number of live cells in untreated control wells. The IC 50 was derived from the survival curve by Sigmoid-E max non-linear regression analysis using GraphPad Prism (GraphPad, San Diego, CA).
In vivo studies using xenografted tumor models UG-K3 (Agensys, patient derived ccRCC xenograft), SKRC-01 (25) Tumor size was measured every 3 to 4 days using calipers.
For the orthotopic model, 1.5 million of UG-K3 viable cells were surgically implanted into the kidneys of male SCID mice. The tumors were allowed to grow for 7 days at which time animals were randomized to different groups (n= 10 per group) and treated, q4dx4. At the end of the study (day 41), the animals were sacrificed and the right and left kidneys weighed. The tumor weights were the weight of the tumor-bearing right kidney minus the weight of the tumor-free contralateral kidney.
Statistical analysis of the tumor volume data for the last day before animal sacrifice was performed using the Kruskal-Wallis test. The implementation of the Kruskal-Wallis test was carried out using the parametric ANOVA F-test on the ranks of the data. Pairwise comparisons were made using the Tukey-Kramer method (2-sided).
Detection and quantitation of Cys-mcMMAF in vivo
Mice bearing 150 mm 3 UG-K3 xenografted tumors were treated with AGS16F (10 mg/kg) or AGS16-7.8 (9.5 mg/kg) by iv injection (day 0). Lysosomes were visualized by staining with antibody directed against the lysosome-associated membrane protein 1 (LAMP1; Cell Signaling Technology) and a secondary antibody, Alexa Fluor® 568-labeled goat anti-rabbit IgG (Invitrogen). Nuclei were visualized with TOPRO®-3 Iodide (Invitrogen). Laser confocal image sections were acquired using a Leica TCS SP5-II).
Binding and degranulation studies with basophils F(ab')2 fragments were generated by digestion with pepsin. The fragments were biotinylated using E-Z-Link Sulfo-NHS-LC-Biotin (Thermo Scientific). Normal donor human and cynomolgus monkey fresh whole blood samples were obtained from Bioreclamation (Baltimore, MD). Goat-anti-hIgE antibody (Invitrogen) or PBS was added to human or cynomolgus monkey whole blood (1 μg/mL) and incubated at 37 °C for 15 minutes. Next, triplicate sample of blood cells were washed and incubated with the F(ab')2 fragments to a final concentration of 1 μg/mL and incubated at 4 °C for 1.5 hours, washed, stained with anti-hIgE-FITC (Invitrogen) and Streptavidin-PE (Jackson Immunoresearch, West Grove, PA), and analyzed in a FACScan (Beckton Dickenson).
For degranulation studies, blood samples (Bioservices, LLC, Reseda, CA) were incubated with AGS16F or anti-hIgE (Invitrogen) and histamine release was analyzed by ELISA according to manufacturer's protocol (Immunotech). Any response from a test substance greater than 5% of total histamine (after subtraction of spontaneous release values) was regarded as positive (17) . 
Mechanism of action and biomarker studies
RESULTS
ENPP3 target identification and expression in normal tissues and cancer
SSH showed that ENPP3 mRNA was differentially expressed in tumor samples from patients with kidney cancer and normal tissues. Highest levels of mRNA for ENPP3 were confirmed by qPCR in several tumor specimens from patients with kidney cancer, while expression was minimal in normal tissues.
IHC studies using an anti-human ENPP3 antibody showed moderate to strong staining in a subset of tubules in the kidney cortex ( Figure 1A In colon cancer specimens, expression of ENPP3 was observed in 10/32 (31.3%) primary tumor TMA samples and 3/21 (14.3%) metastatic TMA samples and nearly all of the tissues had low level expression. Likewise, the expression in ovarian endometrioid cancer was low. This pattern of expression provides a strong rationale for use of an ENPP3 targeted ADC for treatment of ccRCC and subsets of prCC and HCC.
Antibody development and selection of ADC platform
Fully human antibodies were generated in XenoMouse® transgenic mice following immunization with the ENPP3 ECD protein. Anti-ENPP3 antibodies were selected based on affinity and epitope specificity, as well as internalization and cross-reactivity to cynomolgus monkey ENPP3. Selected antibodies produced in hybridoma cells were conjugated to either vcMMAE or to mcMMAF and tested for in vitro cytotoxicity against KU812 cells, a basophilic leukemia line which expresses endogenous ENPP3 (11) .
Among all ADC tested, those comprising Abs AGS16-7.8 and AGS16-9.69 conjugated to either vcMMAE or mcMMAF showed the highest cytotoxic potency in vitro (Figure 2A) , with IC 50 ranging from 0.06 to 0.12 nM (Figure 2A inset) . Therefore, these ADCs were selected for testing in the ENPP3 positive, UG-K3 xenograft model of a patient-derived ccRCC.
In Vivo Studies
As shown in Figure 2B (inset), ENPP3 expression is high and homogenous in xenografted UG-K3 tumors. Treatment with ADC on days 0, 3, 7 and 10 comprising AGS16-9.69 or AGS16-7.8 conjugated to mcMMAF at 3 mg/kg effectively inhibited tumor growth for up to 50 days after the first dose, while ADCs conjugated to the cleavable vcMMAE did not ( Figure 2B) . The levels of AGS16-7.8 conjugated to mcMMAF or vcMMAE in blood two days after last dose were 75±10.8 and 65±9.5 g/ml (average, STD) respectively, ruling out different exposure as a reason for the difference in activity. While AGS16-9.69 and AGS16-7.8 conjugated to
mcMMAF had similar anti-tumor activity, the affinity of AGS16-9.69 for cynomolgus monkey ENPP3 was not considered optimal for future nonclinical studies (data not shown) and AGS16-7.8 conjugated to mcMMAF was selected for further development.
Initially, AGS16-7.8-mcMMAF ADC was produced in hybridoma cells (AGS-16M8F) and later in CHO cells (AGS-16C3F). Both were found to be comparable and used during the Phase I clinical trial having similar abilities to a) bind to the ENPP3 ECD, b) bind to KU812 cells, c) induce cytotoxicity in vitro, and d) inhibit tumor growth in vivo (Supplemental Table 2 ).
Therefore, in the remainder of this manuscript, both the hybridoma and CHO-derived ADC will be referred to as AGS16F.
Biological Characterization of AGS16F
Binding and cytotoxicity of AGS16F and its active metabolite ADCs engineered with mcMMAF are internalized and catabolized to yield the active metabolite Cys-mcMMAF (24) . The IC 50 for of AGS16F and Cys-mc-MMAF against KU812 cells were 0.12 nM and 113 nM. Thus, when delivered extracellulary, the parent ADC has approximately 1000-fold higher potency than the active metabolite. These findings demonstrate the intracellular targeting capability of the antibody and poor bystander effect of the active metabolite, consistent with previous reports showing poor membrane permeability mainly due to the charged C-terminal phenylalanine residue in MMAF (24) .
Cross-reactivity with other ENPP family members and other species
The sequence homologies of ENPP3 with ENPP1 and ENPP2 are 53% and 44%, respectively, while homologies with other ENPP family members range from 15% to 18%. Therefore, the ability of AGS16-7.8 to recognize the ECD of ENPP1 and ENPP2 was examined by ELISA using the corresponding extracellular domains. ELISA binding assays showed strong binding of AGS16-7.8 to the ENPP3 ECD, but no binding to the ECD of ENPP1 or ENPP2 (Supplemental 
the affinity for human ENPP3 in KU812 cells, Kd= 0.08 and 0.25 nM respectively. Despite high homology of human ENPP3 with rat or mouse ENPP3 (87%), in vitro testing showed negligible binding to ENPP3 from both species (data not shown).
Effect of AGS16-7.8 on ENPP3 enzymatic activity
The potential effect of AGS16-7.8 on the enzymatic activity of ENPP3 was investigated using a purified ENPP3 ECD fragment and pNP-TMP as a substrate. As shown in Supplemental Figure   2 , AGS16-7.8 does not inhibit the phosphodiesterase activity of purified ENPP3.
Epitope mapping
The location of the epitope for AGS16-7.8 was analyzed using various His-tagged fragments of the ENPP3 ECD (see Supplemental Figure 3A ): 1) ENPP3 full length ECD (amino acids 46 to 875); 2) ENPP3 ECD fragment 2, which includes the somatomedin-B-like domains (amino acids 46 to 157); 3) ENPP3 ECD fragment 3, comprising the catalytic domain (amino acids 157-558); and 4) ENPP3 ECD fragment 4, comprising the catalytic and nuclease domains (amino acids 157-875). AGS16-7.8 was able to bind to fragments 1 and 4, but not to fragments 2 and 3 (Supplemental Figure 3B) , suggesting that the binding epitope may reside within residues 558 to 875, in a region encompassing the nuclease domain. Binding of AGS16-7.8 to this region is consistent with the lack of inhibition of the enzymatic activity of purified ENPP3 by AGS16-7.8. Altogether, the data indicate that AGS16F is internalized and co-localized to lysosomes as early as 30 minutes after exposure to ENPP3-expressing cells.
AGS16F Internalization Studies
AGS16F Binds to Human and Cynomolgus Monkey Blood Basophils
ENPP3 is expressed on the surface of human basophils and mast cells and expression is rapidly and dramatically up-regulated after crosslinking of FcεRI or stimulation with anti-IgE antibodies (27, 28) . These observations raised the concern that AGS16F could induce degranulation of basophils/mast cells. To address this issue, the binding of AGS16-7.8 and AGS16F to human and cynomolgus monkey basophils in whole blood were examined. F(ab) 2 fragments were used to avoid interactions with Fc receptors in basophils. As shown in Table 1 (25) . Similar results were obtained with blood from cynomolgus monkeys. These data indicate that AGS16F binds to ENPP3 present in whole blood basophils from both humans and cynomolgus monkeys.
The potential effect of AGS16-7.8 and AGS16F on basophil degranulation and histamine release in human blood was investigated. After subtraction of spontaneous release, the positive control (anti-hIgE) should induce release of more than 5% of the total histamine content in 80-90% of donors (29) . Results showed that anti-hIgE treatment, but not AGS16F up to 100 µg/mL (67 nM), induced release of 5.7% to 52.1% of total histamine from the blood samples of 5 different donors.
Therefore, AGS16F does not trigger histamine release from whole blood basophils in vitro.
In vivo studies of AGS16F
The pharmacokinetics of AGS16F in mice was examined in male ICR SCID non-tumor bearing mice (Supplemental Figure 4) . The terminal half-life for the ADC and total antibody was 11.9 days and 14.8 days respectively. The degree on deconjugation (ADC Vs total antibody) based on the calculated Area-under-the-curve (AUC) analysis was approximately 32%.
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To better understand the mechanism of action of AGS16F and to evaluate potential pharmacodynamic (PD) markers for clinical trials, we next investigated molecular changes induced in the tumor and in blood upon administration of AGS16F to UG-K3 tumor bearing mice.
One possible PD biomarker is the caspase cleaved form of cytokeratin-18 (ccCK18), which is formed upon epithelial cell death (30, 31) . Levels of ccCK18 in serum in cancer patients have been used as an early indicator of tumor cell death in clinical trials (32) . Levels of human ccCK18 in blood of UG-K3 tumor bearing mice were measured at 6, 24, 48, 72 h and 7 days after a single dose administration of AGS16F at 3 or 5 mg/kg (Fig 5A) . The results showed a dose dependent increase in ccCK18 peaking at 48 h post AGS16F administration and declining to similar levels than those of control treated mice at 7 days. Tumor volume was also measured showing a decrease in tumor volume after 7 days for the AGS16F treated mice (Fig 5B) . These data established an association between increased levels of ccCK18 in serum and decreased tumor volume upon AGS16F treatment of tumor bearing mice.
The tumors from this study were also investigated for changes in possible downstream markers of AGS16F activity, changes in morphology, and changes in ADC localization and ENPP3 expression. Like other microtubule disrupting agents, auristatins block cell cycle progression, which may result in increases in phospho-histone H3 (PPH3) and cleaved PARP-1 (33). As expected, levels of cleaved PARP-1 and PPH3 increased with time after AGS16F administration, reaching a peak at approximately 48 h ( Figure 5C,D and Supplemental Figure 5 ) mirroring the increases observed for ccCK18 ( Figure 5A ). H&E staining of the tumors revealed changes in cell morphology (cellular atypia and polymorphism) in the AGS16F treated group after 7 days (Fig 5E) consistent with the changes in cPARP1 and PPH3. The levels of ENPP3 in the tumors did not change with treatment at 6 to 72 hours post dosing. However, an overall lowered ENPP3 staining intensity was observed after 7 days. This is likely due to the fact that cell death is more apparent at day 7 day than at earlier times. Representative images at 24 h and 7 days after dosing are shown in Figure 5F . When dosed at 1 or 5 mg/kg, dose-dependent staining of AGS16F was detected in UG-K3 tumors. Levels of staining were similar from 6 to 72 hours, decreasing at the Taken together, these data suggest maximal activity of AGS16F in the tumor at around 48-72 hours decreasing sharply to approximately pre-dose levels 7 days after dosing. This is despite a long terminal half-life of 11.9 to 14.8 days (Supplemental Figure 4) .
DISCUSSION
Data presented herein show for the first time that ENPP3 is highly and uniformly expressed in RCC, especially in ccRCC, and that an ADC targeting ENPP3 has profound anti-tumor activity in three different ccRCC models. However, AGS16F lacked anti-tumor activity in a HCC xenograft model tested possibly because the expression of ENPP3 is mostly focal which may be a problem for a MMAF containing ADC having minimal bystander effect. ENPP3 expression in normal tissues is minimal with the exception of normal human kidney and in activated human basophils and mast cells (27, 28) . In vitro experiments showed no histamine release upon incubation of human blood with AGS16F. Moreover, there were no signs of allergic reactions to AGS16F in cynomolgus monkeys treated with doses up to 6 mg/kg/week for 4 weeks (Agensys, data on file). Likewise, no overt kidney toxicities were observed (Agensys, data on file). ENPP3 expression in activated basophils, mast cells and a few related cancer cell lines such as KU812 may support testing of AGS16F in the very rare diseases of chronic basophilic leukemia and chronic mast cell leukemia (18, 19) .
The antitumor activity of some ADC arises not only from the delivery of a highly potent toxin to tumor cells, but also from the modulation of the biology of the target and by contributions of the immune system mediated by the Fc region of the antibody (34). These two potential attributes of an ADC can also increase its toxicity by damaging normal tissue in which the target is expressed.
We have shown that the unconjugated antibody AGS16-7.8 did not have significant anti-tumor activity. Further, AGS16-7.8 is a fully human IgG 2 which elicits a much lower effector function than an IgG 1 . This attribute may allow good tolerability by limiting toxicity against normal tissues that might result from IgG effector functions.
The mechanism of action of AGS16F was confirmed in the UG-K3 RCC xenograft model. First, the levels of Cys-mcMMAF, the active metabolite, in tumor-bearing mice following a single injection of AGS16F at 10 mg/kg were approximately 40-fold higher than the in vitro IC 50 during the first 72 hours after dosing, and declined to approximately a level 12-fold higher at day 5. Additionally, IHC analysis demonstrated that AGS16F was localized within the tumor by 6 hours, and the level was maintained until 72 hours, decreasing after 7 days. The tumors presented with increases in the levels of PPH3 and cleaved PARP-1 with time peaking at approximately 48 h and then returned to basal levels at 7 days. These data suggest that AGS16F localization, generation of active metabolite and the appearance of markers of anti-tumor activity have similar kinetics and that maximal activity occurs for up to 3 days, decreasing at 5 days (lower Cys-mcMMAF) with a further decline to approximately pre-dose levels at seven days. These data also suggest that to maximize activity, a once weekly or more frequent dosing may be needed despite AGS16F having a terminal half-life of approximately 12 days. Increases in the apoptotic marker ccCK18 in mouse blood were observed with similar kinetics to the intra-tumor markers of activity. This finding suggests that serial sampling of ccCK18 in blood may be a convenient early biomarker of activity of AGS16F in clinical trials (32) . Representative images of localization of AGS16F and control ADC in FFPE tumor samples using an antibody against MMAF at 24 h and 7 days after dosing.
